NCT02522715View on ClinicalTrials.gov

Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

August 13, 2015

Primary Completion Date

October 16, 2019

Study Completion Date

January 1, 2026

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate CarcinomaRecurrent Prostate CarcinomaStage IV Prostate Cancer AJCC v7
Interventions
DRUG

Cabazitaxel

Given IV

DRUG

Enzalutamide

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Prednisone

Given PO

Trial Locations (3)

97239

OHSU Knight Cancer Institute, Portland

Portland VA Medical Center, Portland

98109

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

lead

OHSU Knight Cancer Institute

OTHER

NCT02522715 - Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter